Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Overexpression of Met tyrosine kinase receptor is associated with poor prognosis. Overexpression, and particularly MET amplification, are predictive of response to Met-specific therapy in preclinical models. Immunohistochemistry (IHC) of formalin-fixed paraffin-embedded (FFPE) tissues is currently used to select for 'high Met' expressing tumors for Met inhibitor trials. IHC suffers from antibody non-specificity, lack of quantitative resolution, and, when quantifying multiple proteins, inefficient use of scarce tissue. METHODS: After describing the development of the Liquid-Tissue-Selected Reaction Monitoring-mass spectrometry (LT-SRM-MS) Met assay, we evaluated the expression level of Met in 130 FFPE gastroesophageal cancer (GEC) tissues. We assessed the correlation of SRM Met expression to IHC and mean MET gene copy number (GCN)/nucleus or MET/CEP7 ratio by fluorescence in situ hybridization (FISH). RESULTS: Proteomic mapping of recombinant Met identified 418TEFTTALQR426 as the optimal SRM peptide. Limits of detection (LOD) and quantitation (LOQ) for this peptide were 150 and 200 amol/µg tumor protein, respectively. The assay demonstrated excellent precision and temporal stability of measurements in serial sections analyzed one year apart. Expression levels of 130 GEC tissues ranged (<150 amol/µg to 4669.5 amol/µg. High correlation was observed between SRM Met expression and both MET GCN and MET/CEP7 ratio as determined by FISH (n = 30; R2 = 0.898). IHC did not correlate well with SRM (n = 44; R2 = 0.537) nor FISH GCN (n = 31; R2 = 0.509). A Met SRM level of ≥1500 amol/µg was 100% sensitive (95% CI 0.69-1) and 100% specific (95% CI 0.92-1) for MET amplification. CONCLUSIONS: The Met SRM assay measured the absolute Met levels in clinical tissues with high precision. Compared to IHC, SRM provided a quantitative and linear measurement of Met expression, reliably distinguishing between non-amplified and amplified MET tumors. These results demonstrate a novel clinical tool for efficient tumor expression profiling, potentially leading to better informed therapeutic decisions for patients with GEC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · cited 1×
“Specifically, MET gene amplification and consequent overexpression is an ‘oncogenic driver’ in a subset (,5%) of gastric and esophageal adenocarcinomas [4,11–14], while MET mutations have been rarely reported in various hereditary and sporadic cancers including gastroesophageal adenocarcinomas (GEC) [15].”
Background
Research works printed but not linked: 48
- S Peters, 2012, MET: a promising anticancer therapeutic target, Nat Rev Clin Oncol, 9, 314, 10.1038/nrclinonc.2012.71 · DOI · Paper page
- F Cecchi, 2012, Targeting the HGF/Met signaling pathway in cancer therapy, Expert Opin Ther Targets, 16, 553, 10.1517/14728222.2012.680957 · DOI · Paper page
- L Trusolino, 2010, MET signalling: principles and functions in development, organ regeneration and cancer, Nat Rev Mol Cell Biol, 11, 834, 10.1038/nrm3012 · DOI · Paper page
- DV Catenacci, 2011, RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma, Cancer Biol Ther, 12, 9, 10.4161/cbt.12.1.15747 · DOI
- F Graziano, 2011, Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer, J Clin Oncol, 29, 4789, 10.1200/JCO.2011.36.7706 · DOI · Paper page
- X Liu, 2008, Targeting the Met signaling pathway for cancer therapy, Expert Opin Investig Drugs, 17, 997, 10.1517/13543784.17.7.997 · DOI
- KP Raghav, 2012, cMET and phospho-cMET protein levels in breast cancers and survival outcomes, Clin Cancer Res, 18, 2269, 10.1158/1078-0432.CCR-11-2830 · DOI
- AA Sadiq, 2013, MET as a possible target for non-small-cell lung cancer, J Clin Oncol, 31, 1089, 10.1200/JCO.2012.43.9422 · DOI · Paper page
- N Sharma, 2011, In the clinic: ongoing clinical trials evaluating Met-inhibiting drugs, Ther Adv Med Oncol, 3, S37, 10.1177/1758834011423403 · DOI
- E Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nat Rev Cancer, 12, 89, 10.1038/nrc3205 · DOI · Paper page
- JA Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 · DOI · Paper page
- GA Smolen, 2006, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752, Proc Natl Acad Sci U S A, 103, 2316, 10.1073/pnas.0508776103 · DOI · Paper page
- JK Lennerz, 2011, MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib, J Clin Oncol, 29, 4803, 10.1200/JCO.2011.35.4928 · DOI · Paper page
- PC Ma, 2008, Expression and mutational analysis of MET in human solid cancers, Genes Chromosomes Cancer, 47, 1025, 10.1002/gcc.20604 · DOI · Paper page
- LJ Herrera, 2005, The HGF receptor Met is overexpressed in esophageal adenocarcinoma, Neoplasia, 7, 75, 10.1593/neo.04367 · DOI
- A Sehdev, 2013, Gastroesophageal cancer: focus on epidemiology, classification, and staging, Discov Med, 16, 103
- DV Catenacci, 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence, Cancer Discov, 1, 573, 10.1158/2159-8290.CD-11-0175 · DOI · Paper page
- S Eathiraj, 2011, Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (Met) protein autophosphorylation by ARQ 197, J Biol Chem, 286, 20666, 10.1074/jbc.M110.213801 · DOI
- Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, <etal>et al</etal>.. (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30. · DOI
- BS Pan, 2010, MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated Met receptor, Cancer Res, 70, 1524, 10.1158/0008-5472.CAN-09-2541 · DOI
- KW Rickert, 2011, Structural basis for selective small molecule kinase inhibition of activated Met, J Biol Chem, 286, 11218, 10.1074/jbc.M110.204404 · DOI
- MA Shah, 2013, Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer, PLoS One, 8, e54014, 10.1371/journal.pone.0054014 · DOI · Paper page
- JP Eder, 2009, Novel therapeutic inhibitors of the Met signaling pathway in cancer, Clin Cancer Res, 15, 2207, 10.1158/1078-0432.CCR-08-1306 · DOI · Paper page
- LP Stabile, 2008, Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis, Mol Cancer Ther, 7, 1913, 10.1158/1535-7163.MCT-07-2169 · DOI
- Y Dai, 2010, BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro, Mol Cancer Ther, 9, 1554, 10.1158/1535-7163.MCT-10-0359 · doi:10.1158/1535-7163.mct-10-0359
- N Puri, 2007, A selective small molecule inhibitor of Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts, Cancer Res, 67, 3529, 10.1158/0008-5472.CAN-06-4416 · DOI
- Z Meng, 2011, Targeted mass spectrometry approaches for protein biomarker verification, J Proteomics, 74, 2650, 10.1016/j.jprot.2011.04.011 · DOI
- DC Liebler, 2013, Targeted quantitation of proteins by mass spectrometry, Biochemistry, 52, 3797, 10.1021/bi400110b · DOI · Paper page
- T Hembrough, 2013, Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue, J Mol Diagn, 15, 454, 10.1016/j.jmoldx.2013.03.002 · DOI
- T Hembrough, 2012, Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue, Clin Proteomics, 9, 5, 10.1186/1559-0275-9-5 · DOI
- J Prioleau, 1995, p53 antigen loss in stored paraffin slides, N Engl J Med, 332, 1521, 10.1056/NEJM199506013322217 · doi:10.1056/nejm199506013322217
- TW Jacobs, 1996, Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer, J Natl Cancer Inst, 88, 1054, 10.1093/jnci/88.15.1054 · doi:10.1093/jnci/88.15.1054
- M Mirlacher, 2004, Influence of slide aging on results of translational research studies using immunohistochemistry, Mod Pathol, 17, 1414, 10.1038/modpathol.3800208 · doi:10.1038/modpathol.3800208
- M Gry, 2009, Correlations between RNA and protein expression profiles in 23 human cell lines, BMC Genomics, 10, 365, 10.1186/1471-2164-10-365 · DOI · Paper page
- S von Ahlfen, 2007, Determinants of RNA quality from FFPE samples, PLoS One, 2, e1261, 10.1371/journal.pone.0001261 · DOI · Paper page
- G Sauter, 2003, Tissue microarrays in drug discovery, Nat Rev Drug Discov, 2, 962, 10.1038/nrd1254 · DOI · Paper page
- HE Lee, 2012, MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome, Br J Cancer, 107, 325, 10.1038/bjc.2012.237 · DOI
- Y Toiyama, 2012, Co-expression of hepatocyte growth factor and Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/Met signaling in gastric cancer, Int J Cancer, 130, 2912, 10.1002/ijc.26330 · DOI
- J Zhao, 2011, Up-regulated expression of Ezrin and Met proteins are related to the metastasis and prognosis of gastric carcinomas, Histol Histopathol, 26, 1111
- Catenacci DVT, Henderson L, Peng Xu, Rambo B, Liao WL, <etal>et al</etal>.. (2014) Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity – PANGEA.; Abstr 66, 2014; San Francisco, CA. January 16–18. · doi:10.1200/jco.2014.32.3_suppl.66
- C Gomez-Martin, 2013, Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab, J Clin Oncol, 31, 4445, 10.1200/JCO.2013.48.9070 · DOI · Paper page
- DR Spigel, 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer, J Clin Oncol, 31, 4105, 10.1200/JCO.2012.47.4189 · DOI · Paper page
- Catenacci DVT XP, Henderson L, Liao WL, Burrows J, Hembrough T. (2012) Development of a quantitative gastroesophageal cancer selected reaction monitoring mass spectrometric multi-plex assay for use in FFPE tumor tissues. Poster Presentation at 24th EORTC NCI AACR Symposium, Abstr 561 December 7, 2012. Dublin, Ireland. · doi:10.1016/s0959-8049(12)72358-4
- Hembrough T, Thyparambil S, Henderson L, Rambo B, Cecchi F, <etal>et al</etal>.. (2014) Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue; San Francisco, CA. January 16–18. · doi:10.1200/jco.2014.32.3_suppl.16
- T Stricker, 2011, Molecular profiling of cancer–the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic, Semin Oncol, 38, 173, 10.1053/j.seminoncol.2011.01.013 · DOI
- Khoury J, Catenacci DV (in press) Next-Generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med 2014. · DOI
- G Athauda, 2006, Met ectodomain shedding rate correlates with malignant potential, Clin Cancer Res, 12, 4154, 10.1158/1078-0432.CCR-06-0250 · DOI
- N Archidiacono, 1995, Comparative mapping of human alphoid sequences in great apes, using fluorescence in situ hybridization, Genomics 1995 Jan 20, 25(2), 477
Cited by
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562
Self-citationEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
Self-citationCatenacci, D. V. T., Tebbutt, N. C., Davidenko, I., Murad, A. M., Al-Batran, S.-E., Ilson, D. H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30566-1 · Cited by 348
Self-citationMET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 323
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
Self-citation
Metadata
- Authors
- Catenacci, D. V. T., Liao, W.-L., Thyparambil, S., Henderson, L., Xu, P., Zhao, L., Rambo, B., Hart, J., Xiao, S.-Y., Bengali, K., Uzzell, J., Darfler, M., Krizman, D. B., Cecchi, F., Bottaro, D. P., Karrison, T., Veenstra, T. D., Hembrough, T., & Burrows, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-01
- Volume
- 9
- Issue
- 7
- Pages
- e100586
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2156394972
- Cited by
- 53
- References
- 1
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. https://app.cochat.ai/papers/10.1371/journal.pone.0100586
- The paper
- Catenacci, D. V. T., Liao, W.-L., Thyparambil, S., Henderson, L., Xu, P., Zhao, L., Rambo, B., Hart, J., Xiao, S.-Y., Bengali, K., Uzzell, J., Darfler, M., Krizman, D. B., Cecchi, F., Bottaro, D. P., Karrison, T., Veenstra, T. D., Hembrough, T., & Burrows, J. (2014). Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE. https://doi.org/10.1371/journal.pone.0100586
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.